Literature DB >> 8617417

Hepatitis B and C coinfections and persistent hepatitis B infections: clinical outcome and liver pathology after transplantation.

E J Huang1, T L Wright, J R Lake, C Combs, L D Ferrell.   

Abstract

Hepatitis B virus (HBV) and hepatitis C virus (HCV) infections are common complications after orthotopic liver transplantation (OLT), but the liver pathology and clinical outcomes of HBV infection with HCV coinfection have not been thoroughly examined. In this study, we used the polymerase chain reaction (PCR) to detect HBV and HCV in pre- and post-OLT sera of 38 patients and correlated the findings with clinical outcome and liver pathology. Of 13 patients who were HBV and HCV negative before OLT, 9 acquired HBV infection, and 4 developed acquired HBV and HCV coinfections after OLT. Persistent HBV infections were present in 10 patients. Three patients with pre-OLT HBV infections developed persistent HBV and acquired HCV coinfections after OLT; 5 with pre-OLT HCV infections developed acquired HBV and persistent HCV coinfections after OLT, and 7 had persistent HBV and HCV coinfections before and after OLT. Portal/periportal inflammation was the same in all groups; however, lobular inflammation and fibrosis were more severe in patients with persistent HBV infections and in those with acquired HBV and HCV coinfections. Two major histopathological patterns were present in patients with HBV and HCV coinfections, one with predominant features of HCV infection, and the other with those of HBV infection. Patients with post-OLT HBV and HCV coinfections had survival rates similar to those with acquired HBV infection, whereas patients with persistent HBV infections experienced more allograft loss caused by chronic hepatitis or fibrosing cytolytic hepatitis, and had a more dire clinical outcome than the others. Although the limited numbers reported in this study prevent a definitive conclusion, our data suggest that in patients with HBV and HCV coinfections, the presence of HCV may improve the clinical outcome as compared with the expected outcome of persistent HBV infection alone.

Entities:  

Mesh:

Year:  1996        PMID: 8617417     DOI: 10.1002/hep.510230302

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  7 in total

Review 1.  Hepatitis C and liver transplantation.

Authors:  M Berenguer; T L Wright
Journal:  Gut       Date:  1999-08       Impact factor: 23.059

2.  Viral replication in patients with concomitant hepatitis B and C virus infections.

Authors:  J Crespo; J L Lozano; B Carte; B de las Heras; F de la Cruz; F Pons-Romero
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-06       Impact factor: 3.267

3.  Spontaneous viral clearance after 6-21 years of hepatitis B and C viruses coinfection in high HBV endemic area.

Authors:  Chun-Lei Fan; Lai Wei; Dong Jiang; Hong-Song Chen; Yan Gao; Ruo-Bing Li; Yu Wang
Journal:  World J Gastroenterol       Date:  2003-09       Impact factor: 5.742

4.  Outcome of orthotopic liver transplantation in patients with haemophilia.

Authors:  F H Gordon; P K Mistry; C A Sabin; C A Lee
Journal:  Gut       Date:  1998-05       Impact factor: 23.059

5.  Viral status at the time of liver transplantation for hepatocellular carcinoma: a modern predictor of longterm survival.

Authors:  Ryan T Groeschl; Johnny C Hong; Kathleen K Christians; Kiran K Turaga; Susan Tsai; Charles H C Pilgrim; T Clark Gamblin
Journal:  HPB (Oxford)       Date:  2013-06-19       Impact factor: 3.647

Review 6.  Natural history and treatment of hepatitis B virus and hepatitis C virus coinfection.

Authors:  Seth D Crockett; Emmet B Keeffe
Journal:  Ann Clin Microbiol Antimicrob       Date:  2005-09-13       Impact factor: 3.944

7.  The influence of hepatitis B and C virus coinfection on liver histopathology in children.

Authors:  Maria Pokorska-Śpiewak; Barbara Kowalik-Mikołajewska; Małgorzata Aniszewska; Bożena Walewska-Zielecka; Magdalena Marczyńska
Journal:  Eur J Pediatr       Date:  2014-08-30       Impact factor: 3.183

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.